Abstract A method is provided for generation of bone at a site of an animal where skeletal tissue is deficient comprising administering to the animal, locally at the bone site in the presence of a source of osteogenic cells, an effective amount of a composition comprising TGF- beta in a pharmaceutically acceptable carrier, provided that such composition excludes a bone morphogenetic cofactor, the composition being administered in an amount effective to induce bone growth at the bone site. Also provided is a device for implantation into a site of an animal where skeletal tissue is deficient comprising a device treated with an effective amount of a composition comprising TGF- beta and a source of osteogenic cells in a pharmaceutically acceptable carrier.
A pharmaceutical composition for treatment of a site of an animal where skeletal tissue is deficient consisting essentially of about 1 to 100 ng/ml of TGF-β and an osteogenic cell source isolated from an animal, which composition is formulated in a pharmaceutically acceptable carrier and excludes a bone morphogenetic cofactor.
Claim 2
Dependent Claim
50 words
A pharmaceutical composition for treatment of a site of an animal where skeletal tissue is deficient consisting essentially of about 1 to 100 ng/ml of TGF-β and an osteogenic cell source isolated from an animal, which composition is formulated in a pharmaceutically acceptable carrier and excludes a bone morphogenetic cofactor.
Claim 3
Dependent Claim
21 words
The composition of claim 1 wherein the osteogenic cell source is dispersed whole bone marrow, perichondrium, periosteum, or a cell line.
Claim 4
Dependent Claim
12 words
The composition of claim 1 wherein the TGF-β is TGF-β1 or TGF-β3.